Literature DB >> 26587799

Performance of DWI in the Nodal Characterization and Assessment of Lung Cancer: A Meta-Analysis.

Guohua Shen1, Shuang Hu1, Houfu Deng1, Anren Kuang1.   

Abstract

OBJECTIVE: The purpose of this study is to assess the diagnostic performance of DWI in the N stage assessment of patients with lung cancer.
MATERIALS AND METHODS: The PubMed, EMBASE, Cochrane Library, Web of Science, and EBSCO English-language databases and two Chinese-language databases were searched for eligible studies. On the basis of the data extracted from included studies, we determined the pooled sensitivity and specificity, calculated the positive and negative likelihood ratios, and constructed summary ROC curves. In addition, we also performed threshold effect analysis, metaregression analysis, subgroup analysis, and publication bias analysis to explain the source of heterogeneity.
RESULTS: A total of 18 articles involving 1116 patients met the inclusion criteria. On a per-patient basis, the pooled sensitivity and specificity estimates of DWI were 0.68 (95% CI, 0.63-0.73) and 0.92 (95% CI, 0.90-0.94), respectively. On a per-lesion basis, the corresponding estimates were 0.72 (95% CI, 0.69-0.75) for sensitivity and 0.96 (95% CI, 0.95-0.96) for specificity. Only the analysis method (quantitative vs qualitative) affected the diagnostic accuracy on the basis of subgroup and metaregression analysis.
CONCLUSION: Current evidence suggests that DWI is beneficial in the nodal assessment of patients with lung cancer, and it is necessary to conduct high-quality prospective studies regarding the use of DWI in detecting metastatic lymph nodes of lung cancer to determine its true value.

Entities:  

Keywords:  DWI; N staging; lung cancer; meta-analysis

Mesh:

Year:  2015        PMID: 26587799     DOI: 10.2214/AJR.15.15032

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  9 in total

1.  Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies.

Authors:  Stuart A Taylor; Susan Mallett; Anne Miles; Stephen Morris; Laura Quinn; Caroline S Clarke; Sandy Beare; John Bridgewater; Vicky Goh; Sam Janes; Dow-Mu Koh; Alison Morton; Neal Navani; Alfred Oliver; Anwar Padhani; Shonit Punwani; Andrea Rockall; Steve Halligan
Journal:  Health Technol Assess       Date:  2019-12       Impact factor: 4.014

Review 2.  Economic Benefits and Diagnostic Quality of Diffusion-Weighted Magnetic Resonance Imaging for Primary Lung Cancer.

Authors:  Katsuo Usuda; Aika Funazaki; Ryo Maeda; Atsushi Sekimura; Nozomu Motono; Munetaka Matoba; Hidetaka Uramoto
Journal:  Ann Thorac Cardiovasc Surg       Date:  2017-10-04       Impact factor: 1.520

3.  Diffusion-weighted MRI in solitary pulmonary lesions: associations between apparent diffusion coefficient and multiple histopathological parameters.

Authors:  Feng Zhang; Zien Zhou; Daoqiang Tang; Danni Zheng; Jiejun Cheng; Liaoyi Lin; Jianrong Xu; Xiaojing Zhao; Huawei Wu
Journal:  Sci Rep       Date:  2018-07-26       Impact factor: 4.379

4.  Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial.

Authors:  Stuart A Taylor; Sue Mallett; Sandy Beare; Gauraang Bhatnagar; Dominic Blunt; Peter Boavida; John Bridgewater; Caroline S Clarke; Marian Duggan; Steve Ellis; Robert Glynne-Jones; Vicky Goh; Ashley M Groves; Ayshea Hameeduddin; Sam M Janes; Edward W Johnston; Dow-Mu Koh; Anne Miles; Stephen Morris; Alison Morton; Neal Navani; John O'Donohue; Alfred Oliver; Anwar R Padhani; Helen Pardoe; Uday Patel; Shonit Punwani; Laura Quinn; Hameed Rafiee; Krystyna Reczko; Andrea G Rockall; Khawaja Shahabuddin; Harbir S Sidhu; Jonathan Teague; Mohamed A Thaha; Matthew Train; Katherine van Ree; Sanjaya Wijeyekoon; Steve Halligan
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-05-09

5.  Diffusion-weighted magnetic resonance imaging is useful for the response evaluation of chemotherapy and/or radiotherapy to recurrent lesions of lung cancer.

Authors:  Katsuo Usuda; Shun Iwai; Aika Funasaki; Atsushi Sekimura; Nozomu Motono; Munetaka Matoba; Mariko Doai; Sohsuke Yamada; Yoshimichi Ueda; Hidetaka Uramoto
Journal:  Transl Oncol       Date:  2019-03-09       Impact factor: 4.243

6.  Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial.

Authors:  Stuart A Taylor; Sue Mallett; Simon Ball; Sandy Beare; Gauraang Bhatnagar; Angshu Bhowmik; Peter Boavida; John Bridgewater; Caroline S Clarke; Marian Duggan; Steve Ellis; Robert Glynne-Jones; Vicky Goh; Ashley M Groves; Ayshea Hameeduddin; Sam M Janes; Edward W Johnston; Dow-Mu Koh; Sara Lock; Anne Miles; Stephen Morris; Alison Morton; Neal Navani; Alfred Oliver; Terry O'Shaughnessy; Anwar R Padhani; David Prezzi; Shonit Punwani; Laura Quinn; Hameed Rafiee; Krystyna Reczko; Andrea G Rockall; Peter Russell; Harbir S Sidhu; Nicola Strickland; Kathryn Tarver; Jonathan Teague; Steve Halligan
Journal:  Lancet Respir Med       Date:  2019-05-09       Impact factor: 30.700

7.  FDG-PET/CT and diffusion-weighted imaging for resected lung cancer: correlation of maximum standardized uptake value and apparent diffusion coefficient value with prognostic factors.

Authors:  Katsuo Usuda; Aika Funasaki; Atsushi Sekimura; Nozomu Motono; Munetaka Matoba; Mariko Doai; Sohsuke Yamada; Yoshimichi Ueda; Hidetaka Uramoto
Journal:  Med Oncol       Date:  2018-04-09       Impact factor: 3.064

8.  Relationships and Qualitative Evaluation Between Diffusion-Weighted Imaging and Pathologic Findings of Resected Lung Cancers.

Authors:  Katsuo Usuda; Shun Iwai; Aika Yamagata; Atsushi Sekimura; Nozomu Motono; Munetaka Matoba; Mariko Doai; Sohsuke Yamada; Yoshimichi Ueda; Keiya Hirata; Hidetaka Uramoto
Journal:  Cancers (Basel)       Date:  2020-05-08       Impact factor: 6.639

9.  Correlation between apparent diffusion coefficient and Ki-67 in different pathological types of lung cancer.

Authors:  Hongna Ren; Jianbing Ma; Jia Wang
Journal:  Transl Cancer Res       Date:  2021-12       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.